Test Price
5,000 AED✅ Home Collection Available
Solid Tumor Combo1 Panel: EGFR, ALK, ROS1, MET, PD-L1 Genetic Profiling in UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing using Sanger Sequencing, FISH, and IHC.
- Secure Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval from any accredited UAE hospital; home phlebotomy is disabled for this archival tissue analysis.
- Clinical Guidance: Complimentary telephonic post-test interpretation with a DHA-licensed oncologist to explain your results.
- Insurance: Direct billing verification via WhatsApp at +971 54 548 8731. We handle most UAE networks.
Test Overview & Methodology
The Solid Tumor Combo1 Panel uses three orthogonal technologies—Sanger Sequencing, Fluorescence In-Situ Hybridization (FISH), and Immunohistochemistry (IHC)—to simultaneously detect actionable mutations, gene rearrangements, and immune checkpoint expression (PD-L1) from a single tumor tissue block. This multi-modal approach delivers therapy-directing results for non-small cell lung cancer and other solid malignancies within 5–7 working days, strictly aligned with DHA oncology guidelines.
Comparative Technology Assessment
| Feature | Combo1 Panel | Single-Gene PCR/Sequencing |
|---|---|---|
| Methodology | Multi-modal: Sanger Sequencing, FISH, IHC | Limited to PCR or single-gene sequencing |
| Detection Scope | 5 biomarkers: EGFR mutations, ALK fusions, ROS1 fusions, MET amplification, PD-L1 expression | One or two biomarkers |
| Clinical Actionability | Directly guides TKI, ALK/ROS1 inhibitor, and immunotherapy selection | Partial guidance; may miss co-existing alterations |
| Turnaround Time | 5–7 working days | 7–14 days (sequential testing) |
| Sample Requirement | One formalin-fixed paraffin-embedded (FFPE) block | Multiple sections or fresh tissue |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor | Specialist Diagnostic Radiology (DHA ID: 61713011): “Your tumor’s molecular fingerprint is the most personal guide to treatment. While this panel provides critical markers for targeted therapy and immunotherapy, every result must be interpreted in the full context of your medical history, imaging, and performance status. I encourage you to discuss the findings with your treating oncologist before making any treatment changes.”
Important Advisory
⚠️ Do NOT discontinue or alter any prescribed medication, including targeted therapy or immunotherapy, based solely on this test result. Always consult your prescribing doctor.
Exclusion Criteria & Safety Red Flags
- Insufficient tumor cellularity (<20%) in the biopsy; may require re-biopsy or alternative liquid biopsy.
- Severe bleeding diathesis or anticoagulation that cannot be paused for fresh tissue procurement.
- Acute medical emergencies (e.g., severe dyspnea, hemoptysis, spinal cord compression) – seek immediate ER care.
- Known pregnancy or breastfeeding – testing decisions must involve a maternal-fetal medicine consultation.
- Inability to provide a valid DHA-compliant informed consent; required by Federal Decree-Law No. 4 of 2016 on Medical Liability.
If you experience new or worsening chest pain, uncontrolled bleeding from the biopsy site, or signs of infection (fever >38°C), proceed directly to the nearest emergency department.
Patient FAQ & Clinical Guidance
1. What exactly does the Solid Tumor Combo1 panel detect and why do I need it?
This panel identifies specific genetic mutations (EGFR), gene fusions (ALK, ROS1), amplifications (MET), and the PD-L1 protein expression level—key biomarkers that determine eligibility for precision cancer therapies.
2. How is the test performed and is it painful?
The test requires a small piece of tumor tissue from a previous biopsy or surgical specimen; no additional invasive procedure is needed.
3. Will my insurance cover the 5000 AED cost?
We facilitate direct billing with all major UAE insurers; simply WhatsApp your Emirates ID and policy number for instant verification.
UAE Regulatory & Data Privacy Adherence
All clinical data and personal information are processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your genomic results are encrypted, access-controlled, and never shared without explicit consent.
Clinical & Logistical Metadata
| Test Name | Solid Tumor Combo1 Panel (EGFR, ALK, ROS1, MET, PD-L1) |
| Price (AED) | 5,000 |
| Turnaround Time | 5–7 working days |
| Sample Type / Matrix | Archival Tissue Specimen (FFPE block) – Hospital Extraction Only. Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. |
| Methodology Used | Sanger Sequencing, Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC) |
| ICD-10-CM Code | C34.9 (Malignant neoplasm of unspecified part of bronchus or lung) |
| LOINC Code | 91813-9 (Oncology panel - Lung cancer tissue) |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians